Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: A method and device for calculating design parameters of a design of a progressive spectacle lens on the basis of a predetermined design polygon. The design parameters are calculated by specifying a point within the design polygon, in which the specified point defines the progressive spectacle lens design, and then determining a value of each design parameter at the specified point by an interpolation of at least part of the predetermined values at the corner points and, optionally, of at least part of the predetermined values of the design parameter at the at least one additional point.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: A method for providing spectacle lenses that have a microstructure on at least one side. A procedure is described, in which the structure is introduced into a face of the lens after the processing of the face of the lens. Processing steps used to achieve the optical quality of the corresponding surface can be omitted. The back face of a spectacle lens may be microstructured by CNC-controlled turning after a first shaping processing, wherein the polishing step is omitted.

Abstract: A computer-implemented method and a device for optimizing an optical element comprising at least one diffraction grating, wherein at least one refractive surface contributing to the refractive light deflection and/or the at least one diffraction grating of the optical element are/is optimized in such a way as to minimize the color fringe and at least a second-order aberration of the optical element. Also, a corresponding production method and a corresponding device for producing an optical element comprising at least one diffraction grating.

Abstract: A method for producing a spectacle lens having in particular a diffractive microstructure on at least one lens surface. To this end, a thin structural support layer is initially made available, which on a surface has a microstructure. A lens main body is then cast to the microstructure of the structural support layer.

Abstract: A method for preparing ophthalmic lenses, which have a microstructure on at least one side, particularly a diffractive microstructure for colour fringe correction, wherein the invention provides in particular a method which substantially reduces any adverse effect on the microstructure by damage or soiling during the manufacture of an ophthalmic lens and during the use thereof. Thus a method according to the invention for manufacturing an ophthalmic lens comprises provision of a microstructure on at least one first surface of an ophthalmic lens glass and application of at least one protective coating on the ophthalmic lens glass in such a manner that the protective coating at least partially covers the microstructure, wherein the protective coating has a refractive index which differs from the refractive index of the ophthalmic lens glass.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: A method for producing a series of base lenses, which cover a predetermined power range, wherein each base lens of the series has a base power different from the base powers of the other base lenses of the series, and has at least one diffractive base grating, the method comprising: specifying the base powers of each base lens of the series and calculating the base grating of each base lens of the series so as to minimize the color fringe of the respective base lens with the specified base power in a predetermined region of the spectacle lens.

Abstract: Optimization and production of a spectacle lens for a specific wearing situation for correcting at least one astigmatic refraction of an eye of a spectacles wearer, which in a reference viewing direction of the eye has a cylinder reference value and a cylinder reference axis, comprising: specifying an object distance for at least one evaluation point of the spectacle lens; determining a transformed astigmatic refraction for the at least one evaluation point of the spectacle lens from the cylinder reference value and the cylinder reference axis depending on the specified object distance; and optimizing the spectacle lens such that for the at least one evaluation point a correction of the transformed astigmatic refraction by the spectacle lens in the specific wearing situation is taken into consideration, wherein determining the transformed astigmatic refraction comprises determining a transformed cylinder value and/or a transformed cylinder axis depending on the specified object distance.

Abstract: The present invention relates to 1-aza-bicy-cloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R?); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.

Abstract: A computer-implemented method for calculating or optimizing a spectacle lens for at least one eye of a spectacle wearer. Refraction data of the at least one eye of the spectacle wearer is collected. An individual eye model is defined, wherein the eye model defines at least the topography of a corneal front surface of the at least one eye, position and power of a lens of the eye, and a retina position of the eye such that the eye exhibits the collected refraction data. A first surface and a second surface for the spectacle lens to be calculated or optimized is specified. The path of a main ray through at least one visual point of at least one spectacle lens surface to be calculated or optimized is determined. A spherical wavefront incident on the first surface of the spectacle lens along the main ray is specified.

Abstract: The present invention relates to a method for the quantitative determination of an impurity present in a peptide product, wherein the impurity cannot be separated from other impurities or the main product. The method particularly involves the use of high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC). The method can be used for the investigation of the quality of peptides and proteins, particularly of pharmaceutical peptides and proteins.

Abstract: The present invention relates to a method for the quantitative determination of an impurity present in a peptide product, wherein the impurity cannot be separated from other impurities or the main product. The method particularly involves the use of high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC). The method can be used for the investigation of the quality of peptides and proteins, particularly of pharmaceutical peptides and proteins.

Abstract: Disclosed is a rotor (1) for an electric rotor motor, consisting of a rotor bell (2) with a peripheral wall (4) and at least one one-sided rotor base (6) to enclose a stator, in particular as a part of a motor housing with a high IP rating, for example IP54 per DIN/IEC-EN 60034-5. The rotor bell (2) features a heat sink (12) with high heat conductivity that extends through the rotor base (6) in such a way that the motor heat arising on the inside can be removed via the heat sink (12) through the rotor base (6) to the outside into the environment. Further, the invention relates to an electric rotor motor, in particular with an encapsulated motor housing with a high IP-protection system, for example IP54 per DIN/IEC-EN 60034-5, consisting of a stator and a rotor (1) enclosing the stator in an embodiment of the above-described type.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: The invention relates to a method, a computer program product and a system for designing or producing a spectacle lens for a spectacle wearer. Said method consists of the following steps: individual user data or application data of the spectacle wearer is obtained; the design concept for the spectacle lens having a plurality of evaluation points is determined; a main beam path through the plurality of evaluation points is determined; a local wavefront is specified for each of the main beams in the surroundings of the respective main beam; optical properties of the spectacle lens are determined on the evaluation points by determining an influence of the spectacle lens on the local wavefronts in the surroundings of the respective evaluation point; and the design concept is evaluated in accordance with the determined optical properties and the individual user data.

Abstract: The present invention relates to a polypeptide having interleukin-10 function, comprising two interleukin-10 monomer subunits covalently linked by a linker. The present invention further relates to a nucleic acid molecule encoding the polypeptide of the invention, a vector comprising said nucleic acid molecule, a non-human host transformed with the nucleic acid molecule or the vector of the invention as well as a method for the production of a recombinant polypeptide of the invention. The present invention further relates to a pharmaceutical composition as well as to the polypeptide, the nucleic acid molecule, the vector or the host or host cell of the invention for use in treating and/or preventing inflammatory diseases.

Abstract: The present invention relates to a method for the quantitative determination of an impurity present in a peptide product, wherein the impurity cannot be separated from other impurities or the main product. The method particularly involves the use of high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC). The method can be used for the investigation of the quality of peptides and proteins, particularly of pharmaceutical peptides and proteins.